Menu +

Patient Reimbursement Support Services

Corcept is committed to every Cushing's syndrome patient whose doctor prescribes Korlym® receiving it. We have an active program of reimbursement services and assistance programs designed to help Korlym patients. These programs include:

  1. Coverage and Reimbursement services, including scheduling of shipments
  2. Copay support of up to $5000 per year for qualifying patients
  3. Free drug through our Patient Assistance Program for uninsured patients

We also provide referrals to independent non-profit organizations that help patients find insurance and support copay costs for patients.

These programs ensure that most patients have access to Korlym regardless of their ability to pay. For more information about Korlym support programs go to http://www.korlym.com/patient/resources.php

Indications and Usage

Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Important Limitations of Use

Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome

WARNING: TERMINATION OF PREGNANCY

Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

Please see Full Prescribing Information and Medication Guide.

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue